Recent updates: EU pharmacovigilance legislation

I caught up on how the EU pharmacovigilance legislation has been progressing today on the EMAs website. I wanted to highlight a few of the most recent developments that will be affecting the pharma industry. There is lots of information being released to help guide, advise and influence the integration of the new legislation into pharma's pharmacovigilance strategy and operations. …

What do the industry think about pharmacovigilance for #biosimilars

I have had the pleasure of attending the first ever Biosimilar Drug Development World Europe this week in west London. There has been lots of great conversations about the opportunities that biosimilars present to health care systems across the globe as well as the many hurdles that the industry needs to find solutions too before the potential of these complex …

How can #pharma use You Tube to help build trust in patient safety?

How is pharma communicating their pharmacovigilance and safety strategies out to the patient using online video? I spent some time browsing You Tube this morning to see how pharma is using this tool to communicate the extensive and important work in pharmacovigilance and patient safety. This seems to me to be a great opportunity to build trust with the patient …

Looking back at 2011’s WDSC #drugsafety event

Drug safety and risk management strategy excellence: I thought 2011's drug safety event was a great success and wanted to provide a little insight into it. I've included some photos for you including the presenters, panellists, round table discussion sessions, networking session and delicious food!   Planning for the World Drug Safety Congress Europe 2012 is well underway and based …

Which #drugsafety experts are speaking at WDSC Europe?

  Speakers confirmed to date for WDSC include experts in drug safety, pharmacovigilance, risk management, signal management, epidemiology, medical information and benefit risk. Production on the World Drug Safety Congress Europe 2012 is going really well with an exceptional speaker panel lined up already. Review the list of experts confirmed to speak at the meeting below who will provide insight …

Download presentation from #drug safety expert José Vega, Amgen

Drug safety expert Dr José Vega from Amgen presented at the World Drug Safety Congress Americas in 2011 and you can now download his presentation here! Dr José Vega is Vice President Global Safety, Amgen and in this presentation entitled “Drug safety: emerging trends and future directions for the biopharmaceutical industry” he looks at • The growing importance of observational …

Top themes for 2012 – EU legislation, signal analysis and benefit risk

Top drug safety themes for 2012 – EU legislation, signal analysis and benefit/risk. The World Drug Safety Congress Europe 2012 has a brand new producer working on it, our in- office action man, Nick. He is bringing some fresh eyes to the event and has spent the last few weeks researching the topic inside and out. He has been speaking …

New European pharmacovigilance legislation – what are pharma saying about it?

The new European pharmacovigilance legislation for human use – how is the industry responding to the changes and what are they expecting the impact will be on safety strategy and practical implications. We've been listening to the industry on this and its been great hearing what pharma has to shout about including their expectations, the good, the bad and the …